Choose Language
Select a language for news translation.
Written by John Bromels for The Motley Fool -> Shares of Danish drugmaker Novo Nordisk fell nearly 10% today. The drop came after an experimental cardiovascula…
In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) crossed below their 200 day moving average of $106.41, changing hands as low as $106.29 per shar…
Written by Matthew Benjamin for The Motley Fool -> Both companies are giants in diabetes and obesity treatments. Lately, Eli Lilly has moved ahead in the obe…
Affiliate links on Android Authority may earn us a commission. Learn more. This spring, Google debuted a new category of Android-powered laptops called Google…
Novo Nordisk A/S (NYSE: NVO ) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday. The firm claimed that Li…
Written by James Brumley for The Motley Fool -> Novo Nordisk has run into unexpected headwinds lately, but all these challenges (and then some) may already be …
Included alongside a slew of transfers this offseason, there's intrigue surrounding former Oregon quarterback Austin Novosad at Bowling Green.
Luiz Carlos Barreto, one of the driving forces of the Cinema Novo movement in the 1960s and 1970s, died in Rio de Janeiro on Wednesday, July 22, at the age of …
Written by John Bromels for The Motley Fool -> Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo …
Drugmaker Novo Nordisk sued rival Eli Lilly on Tuesday, accusing the company of false advertising over the performance of its weight loss drugs. The lawsuit, f…
The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action accusing its arch rival Eli Lilly of false advertising in suggesting its weight-loss d…
